证券代码：688338 证券简称：赛科希德 公告编号：2025-047 北京赛科希德科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 重要内容提示： 会议召开地点：上海证券交易所上证路演中心（http://roadshow.sseinf o.com/） 投资者可于 2025 年 11 月 25 日 （星期二） 至 12 月 01 日 （星期一）16: 00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 invest or@succeeder.com.cn 将需要了解和关注的问题提前提供给公司。公司将在说明会 上对投资者普遍关注的问题进行回答。 北京赛科希德科技股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日在 上海证券交易所网站（www.sse.com.cn）披露了《北京赛科希德科技股份有限公司 2025 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025 年第三季 度的经营成果、财务状况、发展理念，公司计划参与 2025 年 12 月 02 日（星期二） 11:00-12:00 举行 2025 年第三季度业绩说明会，此次活动将采用网络文字互动的 ...

证券代码：688338 证券简称：赛科希德 北京赛科希德科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年十一月 北京赛科希德科技股份有限公司 2025 年第二次临时股东大会 北京赛科希德科技股份有限公司 2025 年第二次临时股东大会会议资料 目录 | 2025 | | 年第二次临时股东大会会议须知 3 | | --- | --- | --- | | 2025 | | 年第二次临时股东大会会议议程 5 | | 2025 | | 年第二次临时股东大会会议议案 7 | | | 议案一 | 关于取消监事会及修订《公司章程》的议案 7 | | | 议案二 | 关于公司制定、修订、废止公司部分治理制度的议案 9 | 北京赛科希德科技股份有限公司 2025 年第二次临时股东大会 北京赛科希德科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股 东大会的顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》以及《北京赛科希德科技股份有限公司章程》等相关 规定，特制定北京赛科希德科技股份有限公司（以 ...

Core Viewpoint - The company has experienced significant shareholder reductions and a decline in financial performance in 2025, indicating potential concerns regarding investor confidence and operational efficiency [1][2][3] Shareholder Reduction - Major shareholder Zhang Haiying has reduced holdings by 825,195 shares, representing 0.7774% of the total share capital, with a total reduction amounting to approximately 22.84 million yuan [1] - Other board members, including Gu Xiaofeng and Ding Zhonghui, have also reduced their holdings by 250,000 shares (0.2355%) and 235,000 shares (0.2214%) respectively, with total amounts of 6.468 million yuan and approximately 5.9896 million yuan [2] - Senior management member Zhang Jiahong has reduced his holdings by 600,000 shares (0.5653%), amounting to 16.164 million yuan [2] Financial Performance - For the first three quarters of 2025, the company reported total revenue of 196 million yuan, a decrease of 13.62% compared to the same period last year [3] - The net profit attributable to shareholders was 64.56 million yuan, down 22.83% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 60.73 million yuan, reflecting a decline of 25.98% compared to the previous year [3] - The net cash flow from operating activities was 48.63 million yuan, a decrease of 28.78% year-on-year [3]

Group 1 - Jilin Chemical Fiber's controlling shareholder, Jilin Chemical Fiber Group, completed a capital increase and share expansion, raising registered capital from 809 million to 2.508 billion yuan, with the State-owned Assets Supervision and Administration Commission's shareholding increasing to 67.09% [2] - Lepu Medical's subsidiary received NMPA registration approval for a rechargeable implantable deep brain stimulation system, aimed at assisting patients with advanced Parkinson's disease [3] - Zhenai Home announced a potential change in control, leading to a stock suspension starting November 5, 2025, due to ongoing negotiations [4] Group 2 - Yutong Bus reported a 5.62% year-on-year decline in October sales, with total sales for the year increasing by 5.87% [11] - Qianli Technology's October sales surged by 111.44%, with significant growth in both new energy and other vehicle categories [12] - Sike Xide's major shareholder completed a reduction of 825,195 shares, raising a total of approximately 22.84 million yuan [14] Group 3 - Far East Holdings' subsidiary secured contracts exceeding 1 billion yuan in October, which is expected to positively impact future performance [24] - Quan Yang Quan's subsidiary won a 1.48 billion yuan project for airline drinking water supply, anticipated to enhance future earnings [25] - Guoji Automobile's subsidiary won an 8.09 billion yuan project for a lightweight component factory, expected to positively influence operational performance [26]

证券代码：688338 证券简称：赛科希德 公告编号：2025-046 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份。 减持计划的实施结果情况 公司于 2025 年 7 月 14 日在上海证券交易所网站（www.sse.com.cn）披露了 《北京赛科希德科技股份有限公司股东减持股份计划公告》（公告编号： 2025-031），公司股东张海英女士因自身资金需求，拟通过集中竞价等方式减持 公司股份数量不超过 1,061,424 股,不超过公司总股本比例的 1.00%。 近日，公司收到张海英女士出具的《关于减持结果的告知函》，截至 2025 年 11 月 03 日，公司股东张海英女士通过集中竞价方式累计减持公司股份 825,195 股，占公司总股本的 0.7774%。本次减持计划时间区间已届满。现将相 关情况公告如下： 北京赛科希德科技股份有限公司 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东持股的基 ...

Core Points - The company, Saikexide (688338.SH), announced that shareholder Zhang Haiying has reduced her stake in the company by 825,200 shares, which represents 0.7774% of the total share capital [1] Summary by Sections - **Shareholder Activity** - Zhang Haiying has completed a share reduction plan, with the total shares reduced being 825,200 [1] - The reduction was executed through centralized bidding [1] - The time frame for this reduction plan has now expired [1]

Core Viewpoint - The major shareholder Zhang Haiying has completed a share reduction plan due to personal funding needs, selling a total of 825,195 shares, which is 0.7774% of the total share capital [1] Summary by Relevant Sections - **Shareholder Reduction Plan** - Zhang Haiying initially planned to reduce holdings by up to 1,061,424 shares, representing 1.00% of the total share capital, between August 4 and November 3, 2025 [1] - The reduction was executed through centralized bidding, with a total of 825,195 shares sold by November 3, 2025 [1] - **Financial Details** - The shares were sold at prices ranging from 26.62 to 28.89 yuan per share, resulting in a total reduction amount of 22.8396 million yuan [1] - After the reduction, Zhang Haiying holds 5,499,130 shares, which is 5.1809% of the total share capital [1]

Company Overview - Founded on May 28, 2003, and listed on the Shanghai Stock Exchange on August 6, 2020, the company is a leading player in the field of thrombus and hemostasis in vitro diagnostics in China, possessing a full industry chain advantage [1] - The company primarily engages in the research, development, production, and sales of diagnostic instruments, reagents, and consumables related to thrombus and hemostasis [1] Financial Performance - For Q3 2025, the company's revenue was 196 million, ranking 33rd out of 39 in the industry, while the net profit was approximately 64.5 million, ranking 13th out of 39 [2] - The industry leader, New Industries, reported revenue of 3.43 billion, and the second leader, Antu Bio, reported revenue of 3.13 billion, with the industry average revenue being 708 million and the median at 330 million [2] - The net profit of the industry leader, Ji'an Medical, was 1.59 billion, and the second leader, New Industries, had a net profit of 1.21 billion, with the industry average net profit at 110 million and the median at 26.19 million [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 4.67%, down from 5.25% in the previous year, which is significantly lower than the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 62.22%, slightly up from 62.13% in the previous year, and higher than the industry average of 56.20% [3] Executive Compensation - The chairman, Wu Shiming, received a salary of 1.12 million in 2024, a decrease of 2,300 from 2023 [4] - The general manager, Wang Hai, earned 450,200 in 2024, also a decrease of 2,300 from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 3.44% to 7,012, while the average number of circulating A-shares held per account decreased by 3.32% to 15,100 [5]

Group 1 - The company reported a revenue of 196 million yuan for the first three quarters of 2025, representing a year-on-year decline of 13.62% [1] - The net profit attributable to the parent company was 64.56 million yuan, down 22.83% year-on-year [1] - The net profit after deducting non-recurring items was 60.73 million yuan, a decrease of 25.98% compared to the previous year [1] - The basic earnings per share stood at 0.62 yuan [1]

Core Insights - The company reported a decline in revenue and net profit for the first three quarters of 2025, with revenue at 196 million yuan, down 13.62% year-on-year, and net profit at 64.56 million yuan, down 22.83% year-on-year [2] - In Q3 2025, the company achieved revenue of 56.71 million yuan, a decrease of 15.97% year-on-year, and net profit of 16.56 million yuan, down 20.91% year-on-year [2] Company Performance - The main products of the company are diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [2] - The management indicated that the decline in sales revenue was influenced by a decrease in demand in the domestic in vitro diagnostic industry [2] Market Strategy - The company is enhancing market development in large and medium-sized hospitals domestically to adapt to changes in market demand [2] - The company is also focusing on expanding its overseas market presence, particularly in regions like Russia and South America, with overseas export business growing by 64.29% year-on-year in the first half of the year [2]